Boston Scientific allies with The Medicines Company on stent launch; Quest shareholders get a quarterly dividend;

@FierceMedDev: Biocartis and VIB join forces to develop unique diagnostic cancer test. Release | Follow @FierceMedDev

@MarkHFierce: An Xconomy contributor offers another point-of-vew on the 23andMe issue - a clash of cultures and business models. More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: 'Worm-shaped' nanoparticles best at infiltrating breast cancer. Story from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: China finally allows the FDA to add inspectors to bolster oversight. More | Follow @GalenMoore

> Boston Scientific ($BSX) and The Medicines Company ($MDCO) sealed a co-promotion deal for Boston Scientific's new Promus Premier drug-eluting platinum chromium coronary stent system. Item

> Quest Diagnostics ($DGX) shareholders are getting a quarterly cash dividend of 30 cents per share. Item

> Simavita, an Australian medical device startup focused on urinary incontinence, raised $14 million in a Canadian IPO. Story

> Med tech regulatory reform is advancing in Japan. Item

> Six startups spun out from university discoveries won city grants to help fuel their development; many are focused on diagnostics and medical devices. Story

Biotech News

@FierceBiotech: Chutes & Ladders this week: GoBalto gets new CEO as founder Chung steps down & more. Feature | Follow @FierceBiotech

@JohnCFierce: Mixed outcome for lifitegrast PhIII, 1 of Fleming Ornskov's 1st deals for Shire-$160M SARcode buyout--hit 1 missed. Release | Follow @JohnCFierce

@DamianFierce: So Geron is soaring on these imetelstat results "embargoed" for Monday. More | Follow @DamianFierce

@EmilyMFierce: With drug-resistant malaria strains on the rise, a new report says basic research for malaria needs a boost. Story | Follow @EmilyMFierce

> Biotech vet joins R&D troika to take compounds from campus to clinic. Story

> Shire's new CEO sees one of his first-round biotech deals sour in PhIII. Article

> Novartis hits PhIII paydirt with promising myeloma drug. Report

> Geron soars as marrow cancer drug shines in preliminary results. Story

Pharma News

@FiercePharma: Whooping cough is making a comeback--and the FDA thinks it might know why. Story from FierceVaccines | Follow @FiercePharma

@EricPFierce: Mylan intends to launch 800 injectable products in next 5 years, 150 in US, now that it own Agila. Yesterday's story | Follow @EricPFierce

@CarlyHFierce: NICE smiles on Sanofi's Aubagio the day after snubbing Lemtrada. Story | Follow @CarlyHFierce

> Feds seize documents from Reckitt Benckiser pharma. Story

> Actavis' former CEO is betting on biosimilars. Article

> AstraZeneca is first to win EU approval for an inhaled 4-in-1 flu vaccine. More